+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Steric constraints in the recognition of peptide substrates for the epidermal growth factor receptor kinase



Steric constraints in the recognition of peptide substrates for the epidermal growth factor receptor kinase



International Journal of Peptide & Protein Research 47(3): 219-226



Epidermal growth factor (EGF) stimulates cellular mitogenesis by binding to and activating its membrane-associated receptor. An important component of signal transduction by the activated receptor is the stimulation of an intrinsic tyrosyl residue-specific protein kinase, which selectively phosphorylates tyrosyl residues in the cytoplasmic tail of the receptor and in other cytoplasmic substrates. A recent study utilizing tyrsub, a new high affinity synthetic peptide substrate for the EGF receptor kinase, provided evidence that in peptide substrate binding, the tyrosyl residue plays the central role in recognition, with residues surrounding the tyrosyl residue contributing to stabilization of docking (Guyer et al. (1994) Arch. Biochem. Biophys. 312, 573-578). A large body of previous work had identified acidic residues near the site of phosphorylation as most important for binding; therefore, other residues in tyrsub appeared to be promising sites for locating spectroscopic reporter groups. Since tyrsub has neutral residues -4 and +4 residues from the site of phosphorylation, we prepared two analogs of tyrsub, in each of which one of those residues was substituted with Cys. These cystyrsubs were found to be effectively phosphorylated by EGF receptor prepared from A431 cells, on stimulation with EGF, with high affinities (K-m(app) = 40-50 mu-M). Modification of the cystyrsubs with iodoacetamide had no deleterious effect on the ability of the peptide to be phosphorylated by the EGF receptor kinase, while the labeling by 5-iodoacetimidofluorescein completely abolished the productive interaction between the peptide and the EGF receptor. This unexpected failure of the fluorescently labeled peptides to be phosphorylated does, however, provide information on steric limitations to recognition of substrates by the EGF receptor kinase.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009456845

Download citation: RISBibTeXText

PMID: 8740973

DOI: 10.1111/j.1399-3011.1996.tb01348.x


Related references

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Tumour Biology 39(3): 1010428317695939, 2017

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?. Cancer Science 107(8): 1134-1140, 2017

Autophosphorylation of the intracellular domain of the epidermal growth factor receptor results in different effects on its tyrosine kinase activity with various peptide substrates. Phosphorylation of peptides representing Tyr(P) sites of phospholipase C-gamma. Journal of Biological Chemistry 266(1): 603-608, 1991

Substrates of the epidermal growth factor receptor-kinase. Cell Biology International Reports 8(8): 619-633, 1984

Insulin-like growth factor-1 receptor/epidermal growth factor receptor (EGFR) heterodimerization and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of Clinical Oncology 24(18_suppl): 13032-13032, 2016

Synthetic peptide substrates for the membrane tyrosine protein kinase stimulated by epidermal growth factor. European Journal of Biochemistry 140(2): 363-368, 1984

The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. Journal of Thoracic Oncology 6(2): 387-392, 2011

Peptide substrate recognition by the epidermal growth factor receptor. Archives of Biochemistry and Biophysics 312(2): 573-578, 1994

Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated "MAP" kinase. Proceedings of the National Academy of Sciences of the United States of America 88(6): 2520-2524, 1991

Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. Journal of Clinical Oncology 32(10): 1084-1086, 2014

Identification and biochemical characterization of novel putative substrates for the epidermal growth factor receptor kinase. Journal of Biological Chemistry 267(8): 5155-5161, 1992

Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. Journal of Biological Chemistry 259(12): 7755-7760, 1984

Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. European Journal of Cancer 49(6): 1458-1466, 2013

Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. ChemoTherapy 57(2): 108-114, 2011

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clinical Cancer Research 12(14 Pt 2): 4416s-4420s, 2006